A multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study

A multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study - A multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026558

Enrollment

5000

Registered

2017-03-17

Start date

2008-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who receive or will receive biologics for rheumatoid arthritis

Exclusion criteria

Exclusion criteria: 1) Patients who receive or have received biologics for any disease other than rheumatoid arthritis 2) Patients judged as inadequate at the discretion of physicians

Design outcomes

Primary

Measure	Time frame
1) Secular changes in patient characteristics at initiation of biologics 2) Retention rate of biologic treatments 3) Efficacy and retention rate of methotrexate treatment	—

Secondary

Measure	Time frame
1) Predictors of discontinuation of biologic and methotrexate treatments 2) Correlation between efficacy of biologic and methotrexate treatments	—

Countries

Japan

Contacts

Public ContactShuji Asai

Nagoya University Hospital Orthopedic Surgery

asai@med.nagoya-u.ac.jp052-744-1908

Outcome results